After Hours
$
56.00
Change
+0.34 +0.60%
Volume
Volume 9,299
Feb 7, 2023, 7:59 p.m.
Quotes are delayed by 20 min
Today's close
$ 55.51
$ 55.67
Change
+0.16 +0.28%
Day low
Day high
$53.50
$57.22

52 week low
52 week high
$38.94
$86.95

Market cap
$4.35B
Average volume
1.09M
P/E ratio
N/A
Rev. per Employee
$29,791
EPS
-8.80
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on CRSP
-
Here Are the Best Tech ETFs for 2023
- Barron's Online
-
Thematic ETFs Look Tempting. Just Say No.
- Barron's Online
-
Crispr Therapeutics started at underweight with $37 stock price target at Morgan Stanley
- Tomi Kilgore
-
Crispr Therapeutics stock price target raised to $69 from $55 at Stifel Nicolaus
- Tomi Kilgore
-
Gene-Editor Crispr Therapeutics CEO Sees Positive Catalysts Ahead
- Barron's Online
-
CRISPR Therapeutics downgraded to in line from outperform at Evercore ISI
- Tomi Kilgore
-
Crispr Therapeutics started at outperform with $98 stock price target at BMO Capital
- Tomi Kilgore
-
Roku, Tesla, and Other Cathie Wood Favorites Are Falling
- Barron's Online
-
FDA Advisors Support the First New Gene Therapy in Nearly 5 Years
- Barron's Online
-
Crispr Therapeutics stock price target cut to $52 from $64 at Stifel Nicolaus
- Tomi Kilgore
-
Intellia Stock Has Tumbled. There Are Issues With Gene-Editing Patents.
- Barron's Online
-
Crispr Therapeutics stock price target cut to $100 from $125 at Evercore ISI
- Tomi Kilgore
-
- Barron's Online
-
Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases
- Barron's Online
-
4 Beaten-Down Biotech Stocks That Could Take Off
- Barron's Online
- Loading more headlines...
Analyst Ratings
-
2 Gene Editing Stocks SunTrust Recommends
- Benzinga.com
-
8 Biggest Price Target Changes For Tuesday
- Benzinga.com
-
Benzinga's Top Upgrades, Downgrades For January 23, 2018
- Benzinga.com
Other News on CRSP
-
This Insider Just Sold Shares of CRISPR Therapeutics AG
- GuruFocus.com
-
ARKK Bears Are Losing Momentum
- Seeking Alpha
-
GREENWOOD CAPITAL ASSOCIATES LLC Buys 3, Sells 2 in 3rd Quarter
- GuruFocus.com
-
Nkarta: Under The Radar Company With Brilliant Results
- Seeking Alpha
-
Editas Medicine: Q3 Update And 2 Clinical Catalysts To Watch
- Seeking Alpha
-
Pfizer: Q3 Earnings Review - Planning For Life After COVID
- Seeking Alpha
-
This Insider Just Sold Shares of CRISPR Therapeutics AG
- GuruFocus.com
-
bluebird bio: Commercial Success Highly Uncertain
- Seeking Alpha
-
Prime Medicine: CRISPR 3.0 Company
- Seeking Alpha
- Loading more headlines...
Press Releases on CRSP
-
mRNA Vaccine and Therapeutics Market Report 2023, Size, Share, Trends and Forecast to 2028
- SUPER MARKET RESEARCH
-
mRNA Vaccine and Therapeutics Market Report 2022, Size, Share, Trends and Forecast to 2027
- SUPER MARKET RESEARCH
-
mRNA Vaccine and Therapeutics Market Report 2022, Size, Share, Trends and Forecast to 2027
- SUPER MARKET RESEARCH
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com